GlobalData on MSN15h
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPA
Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...
Zacks.com on MSN12h
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
At home, no needle: FDA approves first at-home flu shot
A new weapon against flu is now approved by the Food and Drug Administration (FDA).
Daily3d
AstraZeneca FluMist gets USFDA nod for self-administered influenza vaccine
AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...
Managed Healthcare Executive6d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
SMA8d
Ultrasound-aided Spinraza injection cuts needle redirections: Study
Using ultrasound to guide Spinraza injection in SMA adults reduced the number of needle redirections, a study found.
Joplin Globe6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...
Buy6d
AstraZeneca Fasenra treatment for EGPA approved in the US
Approximately half of EGPA patients also have adult-onset severe eosinophilic asthma, or SEA, for which Fasenra is only the second biologic approved treatment. Fasenra is now approved as an add-on ...